Aligos Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 4.8 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 29.97M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG‑055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG‑097558, a small molecule ritonavir‑free pan‑coronavirus protea...